#20 Novartis — Strategic Initiative & Reskilling | Global Intelligence Report 2024-2026

Revenue

$45B

AI Pipeline Target

50%

Sandoz Spinoff

$13B+ value

Focus Areas

CV / Imm / Neuro

Key Strategic Initiative — Review 1: Restructuring Profile

Focused Innovative Medicines Model (Post-Sandoz Spin-Off)

Portfolio Concentration Strategy Stage: Implementation

Post-Sandoz spin-off, Novartis concentrated exclusively on innovative medicines across cardiovascular, immunology, and neuroscience. Deployed AI drug discovery platform, targeting 50% AI-assisted pipeline by 2026. The focused model allowed capital reallocation to high-value therapeutics like Kesimpta, Cosentyx, and Entresto, while building a next-generation AI discovery engine.

Review 2: Reskilling Imperatives — Skill Gap Analysis

Scientific + Digital

AI drug discovery methods

92%

Translational medicine

88%

Precision medicine

86%

Clinical AI tools usage

83%

Portfolio prioritization

85%

Innovative therapeutics R&D

90%

Affected Workforce Segments

Drug discovery scientistsClinical data specialistsCommercial teamsRegulatory affairs

Learning Infrastructure Required

Novartis AI Innovation Lab (Cambridge, MA)
Basel Research Campus learning hub
Partnership with Recursion Pharmaceuticals

Recommended Learning & Reskilling Modalities

1Novartis Learning Academy
2AI drug design certification
3Precision medicine specialisation programs
4Clinical data science masterclasses